Resonance Health (ASX:RHT) Selling and Marketing Expense: A$0.42 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Resonance Health Selling and Marketing Expense?

Resonance Health ASX:RHT Selling and Marketing Expense is A$0.42 Mil as of Jun. 2026. The stock has 5 warning signs investors should review.

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Resonance Health's Selling and Marketing Expense for the six months ended in Jun. 2026 was A$0.32 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.42 Mil.

Resonance Health Selling and Marketing Expense Related Terms

Resonance Health Selling and Marketing Expense Historical Data

* Premium members only.

The historical data trend for Resonance Health's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resonance Health Selling and Marketing Expense Chart

Resonance Health Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.02 0.82 0.91 0.86 0.42

Resonance Health Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.46 0.40 0.10 0.32

Resonance Health Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling and Marketing Expense of A$0.42 Mil mean?
Resonance Health (ASX:RHT) has a Selling and Marketing Expense of A$0.42 Mil as of Jun. 2026. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on Resonance Health and its competitors.
Is Resonance Health's Selling and Marketing Expense too high?
Resonance Health's current Selling and Marketing Expense is A$0.42 Mil.
How does Resonance Health's Selling and Marketing Expense compare to VEEV and BTSG?
Resonance Health's Selling and Marketing Expense of A$0.42 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling and Marketing Expense for a Healthcare Providers & Services company?
A good Selling and Marketing Expense depends on the Healthcare Providers & Services industry context. However, Selling and Marketing Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling and Marketing Expense mean?
A high Selling and Marketing Expense can signal that a stock is expensive relative to its fundamentals. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on Resonance Health and its competitors. Resonance Health's current Selling and Marketing Expense is A$0.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.08, compared to a current price of A$0.06 — trading 26.3% below its estimated fair value. The current Selling and Marketing Expense is A$0.42 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling and Marketing Expense calculated?
Selling and Marketing Expense is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Selling and Marketing Expense is A$0.42 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Resonance Health Business Description

Address 141 Burswood Road, Level 1, Burswood, Perth, WA, AUS, 6100
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.